Intravenous Benign gastric and duodenal ulceration, Hypersecretory conditions
Adult: 20 mg 12 hourly via inj over 2 minutes or via infusion over 15-30 minutes.
Intravenous Gastro-oesophageal reflux disease
Child: Recommended dose: 1-16 years Initially, 0.25 mg/kg 12 hourly via injection over 2 minutes or via infusion over 15 minutes, may increase dose up to 40 mg daily.
Oral Hypersecretory conditions
Adult: Initially, 20 mg 6 hourly, may increase doses up to 800 mg daily, as necessary.
Oral Gastro-oesophageal reflux disease
Adult: 20 mg bid for 6-12 weeks or up to 40 mg bid if there is oesophageal erosion. Maintenance: 20 mg bid. Child: Recommended dose: As oral solution: <3 months 0.5 mg/kg once daily; 3 months-<1 year 0.5 mg/kg bid; 1-16 years 0.5 mg/kg bid up to 40 mg bid.
Oral Non-ulcer dyspepsia
Adult: 10 or 20 mg bid.
Oral Benign gastric and duodenal ulceration
Adult: 40 mg daily at night for 4-8 weeks. Maintenance: 20 mg daily at night. Child: As oral solution: 1-16 years Initially, 0.5 mg/kg at bedtime or in 2 divided doses, may increase dose up to 40 mg daily.
<50 to <10
Reduce dose to half or prolong dosing interval to 36-48 hours based on clinical response.
May be taken with or without food.
IV inj: Dilute 2 mL with 0.9% NaCl inj or other compatible IV solution to a total volume of either 5 mL or 10 mL. IV infusion: Dilute 2 mL with 100 mL of 5% dextrose or other compatible solution.
Patient with chronic lung disease and diabetes. Immunocompromised or intubated (in ICU setting) patient. Rule out gastric malignancy or possibility of malignancy prior to therapy. Renal impairment. Children. Pregnancy and lactation.
Blood and lymphatic system disorders: Rarely, Thrombocytopenia, agranulocytosis, pancytopenia, leucopenia. Cardiac disorders: Arrhythmia, atrioventricular block, palpitations. Ear and labyrinth disorders: Tinnitus. Eye disorders: Orbital oedema, conjunctival injection. Gastrointestinal disorders: Constipation, diarrhoea, taste disorder, rarely, dry mouth, nausea, vomiting, abdominal discomfort or distension. General disorders and admin site conditions: Fever, fatigue, asthenia. Hepatobiliary disorders: Cholestatic jaundice, hepatitis. Immune system disorders: Angioedema. Injury, poisoning and procedural complications: Irritation at injection site (IV). Investigations: Increased liver enzymes. Metabolism and nutrition disorders: Anorexia. Musculoskeletal and connective tissue disorders: Musculoskeletal pain including muscle cramps, arthralgia, rhabdomyolysis. Nervous system disorders: Headache, dizziness, paraesthesia. Psychiatric disorders: Insomnia, somnolence, agitation, seizure, psychic disturbances including hallucinations, confusion, agitation, depression, anxiety. Reproductive system and breast disorders: Decreased libido. Respiratory, thoracic and mediastinal disorders: Bronchospasm, rarely, interstitial pneumonia. Skin and subcutaneous tissue disorders: Acne, dry skin, rash, pruritus, urticaria. Rarely, toxic epidermal necrolysis, Stevens-Johnson syndrome. Vascular disorders: Anaphylaxis, flushing.
This drug may cause dizziness, headache or confusion, if affected, do not drive or operate machinery.
Monitor CBC, gastric pH, liver function (prolonged use), and occult blood with gastrointestinal bleeding.
May decrease serum concentrations of atazanavir, cefditoren, delavirdine, ketoconazole, and fosamprenavir. May decrease the absorption of dasatinib. Probenecid inhibits the renal tubular secretion of famotidine. Antacids may reduce the absorption of famotidine.
Description: Famotidine competitively inhibits histamine at H2-receptors of the gastric parietal cells thereby inhibiting gastric acid secretion and gastric volume. Onset: Antisecretory effect: Within 1 hour (oral). Duration: Antisecretory effect: 10-12 hours (oral, IV). Pharmacokinetics: Absorption: Incompletely absorbed from the gastrointestinal tract. Bioavailability: 40-45% (oral). Time to peak serum concentration: Approx 1-3 hours (oral). Distribution: Crosses placenta and present in breastmilk. Volume of distribution: 1.3±0.2 L/kg. Plasma protein binding: 15-20%. Metabolism: Undergoes minimal first-pass metabolism to form S-oxide. Excretion: Via urine (oral: 25-30%, IV: 65-70% as unchanged drug). Elimination half-life: 2.5-3.5 hours.
Tab/oral solution: Store below 30°C. Protect from light and moisture. Solution for inj: Store between 2-8°C. Do not freeze. Protect from light.